Harrow

US · HROW #3155 by market cap

30.62 +0.27 +0.89%

Live - 5344 symbols - heartbeat 468s ago · 2026-10-08 09:03

Pre-market 30.55 -0.23%

After-hours 31.12 +1.63%

Overnight 30.69 +0.23%

Market cap: 1.15B
P/E (TTM): -30.93
P/B: 75.60
EPS: -0.14
Div yield: 0.00%
52W pos: 8%

Reader sentiment Are you bullish or bearish on HROW?

Anonymous reader poll. Unscientific, not investment advice.

About Harrow

Harrow, Inc. engages in the development, production, and sale of innovative medications. It operates through the following segments: Branded and ImprimisRx. The Branded segment includes activities of the company’s FDA approved ophthalmology pharmaceutical products, including the out-licensing of rights to certain branded products. The ImprimisRx segment represents activities in the company’s ophthalmology-focused pharmaceutical compounding business. The company was founded by Mark L. Baum and Robert J. Kammer on January 11, 2006 and is headquartered in Nashville, TN.

Founded: 2006
CEO: Mr. Mark L. Baum
Employees: 373
Headquarters: Nashville, Tennessee, United States of America
Fiscal year end: 12-31
Website: harrow.com

Company profile

Exchange: US
Symbol: HROW
Market-cap rank: #3155
Market cap: 1.15B
Float cap: 885.83M
Shares out: 37.49M
Float shares: 28.93M

Sectors & themes

Drug Manufacturers - Specialty & Generic Cannabis & Hemp Fractional Shares JP

Browse all sectors & themes

Quote time 2026-10-08 09:03:56 · For reference only, not investment advice and not tailored to your situation.